Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system

Key Points

• The aim is to analyze the safety profile of obinutuzumab, focusing on differences between genders.
• Conducted a pharmacovigilance analysis using the FDA adverse event reporting system.
• Compared reported adverse events between males and females.
• Identified trends related to gender-specific risks.
• Obinutuzumab was associated with a higher rate of adverse events in females compared to males.
• Significant discrepancies in adverse event types were noted based on gender.
• The findings underscore the need for enhanced safety monitoring tailored to gender.